MELBOURNE, Australia, June 3, 2024 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report)’s share price was up 12% during mid-day trading on Friday . The company traded as high as $12.48 and last traded at $12.22. Approximately 7,202 shares were traded during trading, an increase of 18% from the average daily volume of 6,118 shares. The stock had previously closed […]
TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.Reported